Medication Shortages — The Empty Code Cart

A standard postpartum hemorrhage protocol calls for oxytocin first, then misoprostol as a second-line uterotonic, then methylergonovine or carboprost if both fail. In 2026, the average L&D unit at a community hospital cannot reliably stock all four. When oxytocin is on distributor allocation and misoprostol is restricted by the pharmacy's corporate counsel, the unit is left with methylergonovine — which is contraindicated in the hypertensive patient — and carboprost, which is contraindicated in the asthmatic patient. The hypertensive postpartum patient on a magnesium drip, hemorrhaging, with no oxytocin and no misoprostol available, is the patient the supply-chain failure produces. Methergine is not a choice she can safely receive. The cascade is recoverable. The cascade is also a documented mortality pathway.

Magnesium sulfate is the undisputed gold standard for preventing eclamptic seizures in severe preeclampsia. Its administration is not a choice; it is the protocol. In periods of allocation, pharmacies receive partial shipments of the pre-mixed bags and shift to compounding the solution on-site from concentrate — a process that adds twenty to forty minutes to the time-to-administration in a clinical situation where every minute increases the seizure risk. The preeclamptic patient who progresses to eclampsia during the compounding delay is, in the strict clinical sense, the patient the allocation produced. Magnesium has no clinical equivalent. Substitution is not a treatment plan.

Magnesium sulfate is the global maternal-health gold standard precisely because, in the original international trials, it was studied in the intramuscular form — five grams into each buttock, ten grams total — that could be given anywhere there was a body and a syringe. The IM form is what made the drug universal. The IM form is what the textbook teaches you to reach for when the patient is in severe-range hypertension, the peripheral vessels are clamped down, and a line cannot be placed before the seizure window closes. In 2026, in U.S. community hospitals, the IM formulation is, with high frequency, not in the building. The pharmacist has, in many cases, never had occasion to order it. The supply chain that produces it is so concentrated that the regional pharmacist cannot confirm, without calling the manufacturer's rep, whether the formulation is still being produced. The standard order set presumes the line; the rescue presumes the IM dose; the rescue is not there. The pregnant patient whose seizure the IM dose was meant to prevent is the patient the absent rescue produces.

Postpartum hemorrhage occurs in three to five percent of all U.S. deliveries. It accounts for more than ten percent of all maternal deaths. The mortality is, in the population of women with access to a fully stocked code cart and a functional obstetric team, almost entirely preventable. Every uterotonic shortage shifts a fraction of the preventable mortality into the non-preventable column. The shift is not theoretical. It is the mechanism by which the U.S. maternal mortality rate has not improved in twenty years despite spending more on healthcare than any country in the world.

The generic sterile injectable market — which includes oxytocin, magnesium sulfate, and most second-line uterotonics — has consolidated, over the past two decades, to a handful of manufacturers operating on razor-thin margins. The 2024 FDA Drug Shortage Report identified that, for the most-used obstetric injectables, fewer than four manufacturers produce the entire U.S. supply, and for some drugs the number is three or two. When one manufacturer experiences a production interruption — a quality-inspection failure, a raw-material sourcing problem, a labor disruption — the entire national supply contracts within sixty days. The contraction is not a market signal in the textbook sense. It is the predictable consequence of a market structure that has been allowed to consolidate beyond the threshold at which supply redundancy is operationally possible.

When distributors place injectables on allocation, the volume each hospital can purchase is set by historical purchasing volume. Small rural hospitals, critical-access facilities, and freestanding birth centers — purchasers of small volumes — are the first to be completely cut off. The 1,119 counties classified as maternity care deserts by the March of Dimes are also, with high correlation, the counties whose hospitals are most exposed to the allocation-gap mechanism. The supply-chain restriction does not distribute its effect evenly across the U.S. obstetric system. It distributes it onto the patient population already most marginally connected to the system.

The Drug Shortage Prevention and Mitigation Act, in successive Congresses, has proposed to extend FDA authority over allocation decisions made downstream of the manufacturer — at the distributor level — where the operational reality of obstetric shortages is currently produced. The current FDA Drug Shortage authority covers manufacturing output but not the distributor-allocation algorithms that produce the local stockout. The modernization vehicle is named, introduced, and currently in committee in the Senate HELP and House Energy & Commerce committees. The lever is on the appropriations and authorizing calendar.

The CHIPS and Science Act of 2022 provided the policy template for federally financed reshoring of strategically critical manufacturing capacity. The same template has been proposed, in the 119th Congress and previously, for generic-injectable pharmaceutical manufacturing — a category that includes oxytocin, magnesium sulfate, and the broader obstetric formulary. The federal investment required to bring an additional one to two generic-injectable manufacturers online and to maintain the redundancy is, on the most recent BARDA scoring, in the range of $2-3 billion over five years — a fraction of the Medicare and Medicaid downstream costs that the supply chain failures currently produce. The vehicle is the Defense Production Act authority and the BARDA-equivalent funding stream. Both are procedurally available.

The Medicaid Drug Rebate Program, as structured, requires manufacturers to provide their lowest commercial price to Medicaid. For generic injectables operating on razor-thin margins, the rebate structure has, since the 1990s, contributed to the operational decision by individual manufacturers to exit the market — the regulatory math no longer supports continued production. The lever is the Medicaid Drug Rebate reform that would restore a manufacturing margin sufficient to keep the remaining manufacturers in the market and to attract new entrants. The legislative vehicle is the Medicaid Generic Drug Pricing Reform Act, introduced in successive Congresses. The vehicle is procedurally available. The political prerequisite is the appropriations and authorizing committee composition that the 2026 midterm determines.